The companies will develop a mobile app that will allow patients to self-manage symptoms and enable remote monitoring by healthcare providers. In a phone interview, CEO Pierre Leurent touted the platform’s broad applicability across different use cases.
Original Article: BMS, Voluntis partner on digital therapeutics for cancer patients